<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Antiplatelet therapy is important in secondary prophylaxis in patients with ischemic heart, brain and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to investigate the number of patients in Vejle County admitted to hospital in the second half of 2003 with <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> heart, brain and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e> to evaluate the kind of secondary prophylaxis and its duration </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, the study registered the number of patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> treated with antiplatelet therapy </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: The study included 2345 patients with ischemic heart, brain and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e>, and patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients' data and information about medication were obtained from the hospital electronic database and public health insurance of Vejle County </plain></SENT>
<SENT sid="5" pm="."><plain>Antiplatelet therapy was registered up to one year after <z:hpo ids='HP_0003674'>onset</z:hpo> of the disease </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 1121 patients were admitted with <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> (including patients with <z:hpo ids='HP_0001681'>angina pectoris</z:hpo>), 624 patients had cerebral diseases, and 600 had <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="15365">Acetylsalicylic acid</z:chebi> (<z:chebi fb="37" ids="15365">ASA</z:chebi>) and a combination of <z:chebi fb="37" ids="15365">ASA</z:chebi> and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> were the most frequent forms of antiplatelet medication </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and ischemic <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain diseases</z:e> made up 75% of those for whom medication was not registered </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The study shows that in nearly <z:hpo ids='HP_0000001'>all</z:hpo> disease groups no antiplatelet therapy was registered for a very large number of % patients (up to 75%) </plain></SENT>
<SENT sid="10" pm="."><plain>A considerable number % of patients (up to 56%) with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> did not receive sufficient antiplatelet treatment according to Danish recommendations </plain></SENT>
</text></document>